Takeda Pharmaceutical (NYSE:TAK) Shares Gap Down - Here's What Happened

Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report)'s share price gapped down prior to trading on Monday . The stock had previously closed at $14.36, but opened at $13.56. Takeda Pharmaceutical shares last traded at $13.97, with a volume of 770,687 shares changing hands.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

The stock has a 50-day moving average of $14.76 and a 200-day moving average of $14.00. The firm has a market cap of $44.88 billion, a price-to-earnings ratio of 35.26, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. acquired a new position in shares of Takeda Pharmaceutical during the first quarter worth $51,049,000. Goldman Sachs Group Inc. grew its stake in Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock valued at $79,120,000 after acquiring an additional 692,404 shares during the period. Soleus Capital Management L.P. grew its stake in Takeda Pharmaceutical by 136.0% in the fourth quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock valued at $15,623,000 after acquiring an additional 680,000 shares during the period. Toronto Dominion Bank acquired a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $6,760,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Takeda Pharmaceutical by 15,449.0% in the fourth quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock valued at $6,629,000 after purchasing an additional 497,457 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.